Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Metabolics Pharma’s ENT-03 shows promising Phase 1a data in obese and type 2 diabetic patients at ADA 2025 Metabolics Pharma’s ENT-03 shows Phase 1a success in obese and diabetic subjects, with plans for Phase 1b in late 2025. Learn about its brain-based mechanism. byPallavi MadhirajuJune 26, 2025